MAPT and Cognitive impairment: In this study, we first examined differences in neurodegeneration patterns across four CSF Alzheimer’s disease biomarker groups: (i) control group defined as A−T−&CU (amyloid negative, tau negative, cognitively unimpaired); (ii) A+T− (amyloid positive, tau negative); (iii) A+T+ (amyloid positive, tau positive) and (iv) A−T−&CI (amyloid negative, tau negative, cognitive impairment due to other non-Alzheimer’s disease conditions).